Cargando…

Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12

BACKGROUND: While significant strides in the treatment of metastatic bladder cancer have been made with immune checkpoint inhibitors, the treatment of carcinoma in situ and non-muscle invasive, non-metastatic (superficial) human urothelial carcinoma, also termed non-muscle invasive bladder cancer (N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morillon, Y. Maurice, Su, Zhen, Schlom, Jeffrey, Greiner, John W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558846/ https://www.ncbi.nlm.nih.gov/pubmed/31186063 http://dx.doi.org/10.1186/s40425-019-0620-2

Ejemplares similares

NHS-IL12, a Tumor-Targeting Immunocytokine
por: Greiner, John W, et al.
Publicado: (2021)

The immunocytokine NHS-IL12 as a potential cancer therapeutic
por: Fallon, Jonathan, et al.
Publicado: (2014)

Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma
por: Paoloni, Melissa, et al.
Publicado: (2015)

Improved intratumoral penetration of IL12 immunocytokine enhances the antitumor efficacy
por: Jung, Keunok, et al.
Publicado: (2022)

Novel Immunocytokine IL12-SS1 (Fv) Inhibits Mesothelioma Tumor Growth in Nude Mice
por: Kim, Heungnam, et al.
Publicado: (2013)

Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma
por: Pedretti, M, et al.
Publicado: (2010)

Utilizing Immunocytokines for Cancer Therapy
por: Runbeck, Erin, et al.
Publicado: (2021)

Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
por: Klein, Christian, et al.
Publicado: (2017)

An engineered immunocytokine with collagen affinity improves the tumor bioavailability, tolerability, and therapeutic efficacy of IL-2
por: Silver, Aliyah B., et al.
Publicado: (2023)

S41. Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer
por: Klein, C
Publicado: (2014)

The present and future of immunocytokines for cancer treatment
por: Gout, Dennis Y., et al.
Publicado: (2022)

Evaluation of novel immunocytokines that preferentially target high or intermediate affinity IL-2 receptors
por: Perez Horta, Zulmarie, et al.
Publicado: (2014)

Immunocytokines: the long awaited therapeutic magic bullet in rheumatoid arthritis?
por: van de Loo, Fons A, et al.
Publicado: (2009)

Potent immunomodulatory effects of an anti-CEA-IL-2 immunocytokine on tumor therapy and effects of stereotactic radiation
por: Kujawski, Maciej, et al.
Publicado: (2020)

Enhanced immunotherapy by combining a vaccine with a novel murine GITR ligand fusion protein
por: Morillon, Y. Maurice, et al.
Publicado: (2017)

Current and Potential Uses of Immunocytokines as Cancer Immunotherapy
por: Sondel, Paul M., et al.
Publicado: (2012)

Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
por: Vincent, Marie, et al.
Publicado: (2013)

Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2
por: Rekers, Nicolle H, et al.
Publicado: (2015)

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy
por: Waldhauer, Inja, et al.
Publicado: (2021)

Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody
por: Fallon, Jonathan K., et al.
Publicado: (2017)

Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine
por: Smalley Rumfield, Claire, et al.
Publicado: (2020)

Immunocytokines: a review of molecules in clinical development for cancer therapy
por: List, Thomas, et al.
Publicado: (2013)

Development of interferon γ-based immunocytokines targeting renal cancer
por: Chen, Peirong, et al.
Publicado: (2013)

The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
por: Rekers, Nicolle H., et al.
Publicado: (2018)

Potent immunomodulatory and antitumor effect of anti-CD20-IL2no-alpha tri-functional immunocytokine for cancer therapy
por: Casadesús, Ana Victoria, et al.
Publicado: (2022)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2022)

Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15Rα complex
por: Chen, Jihong, et al.
Publicado: (2022)

Tumor regression and immunity in combination therapy with anti-CEA chimeric antigen receptor T cells and anti-CEA-IL2 immunocytokine
por: Cha, Seung E., et al.
Publicado: (2021)

Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts
por: Orecchia, Paola, et al.
Publicado: (2015)

(89)Zr-labeled CEA-targeted IL-2 variant immunocytokine in patients with solid tumors: CEA-mediated tumor accumulation and role of IL-2 receptor-binding
por: van Brummelen, Emilie M.J., et al.
Publicado: (2018)

Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis
por: Schwager, Kathrin, et al.
Publicado: (2009)

The Use of a Humanized NSG-β2m(−/−) Model for Investigation of Immune and Anti-tumor Effects Mediated by the Bifunctional Immunotherapeutic Bintrafusp Alfa
por: Morillon, Y. Maurice, et al.
Publicado: (2020)

In vivo synergy of radiation and hu14.18-IL2 immunocytokine results in a memory T cell response in a syngeneic murine melanoma model
por: Morris, Zachary S, et al.
Publicado: (2014)

Intratumoral injection reduces toxicity and antibody-mediated neutralization of immunocytokine in a mouse melanoma model
por: Baniel, Claire C, et al.
Publicado: (2020)

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma
por: Strauss, Julius, et al.
Publicado: (2023)

Systemic immunotherapy of superficial mouse bladder cancer with Avelumab (MSB0010718C), an anti-PD-L1 immune checkpoint inhibitor
por: Vandeveer, Amanda, et al.
Publicado: (2015)

Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009
por: Pellom, Samuel T., et al.
Publicado: (2021)

NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models
por: Xu, Chunxiao, et al.
Publicado: (2021)

Lithium Monitoring Within NHS Forth Valley 2020
por: Carbarns, Amy
Publicado: (2022)

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma
por: Ribas, Antoni, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_tmt7jr3keuj1sj6nogl6iis8im